Trial | NCT02660593  Report issue

Title

Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes
SanGrow Decoction in Patients With Diabetes- Single Center, Open, and Non-randomized Study

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    20
MedlinePlus related topics: Blood Sugar

Primary Outcome Measures:

Fast glucose and HbA1c change between the baseline and end of study [ Time Frame: From baseline to 30 and 100 days]
[ Designated as safety issue: No ]
Successful rate of blood glucose control (the proportion of patients with HbA1c <7%) [ Time Frame: From baseline to 30 days and 100 days] [ Designated as safety issue: No ]

Secondary Outcome Measures:

• To evaluate the change of quality of life in the 1 months by the health questionnaire SF-36 [ Time Frame: From baseline to month 1 ] [ Designated as safety issue: No ]
This study is aimed to evaluate the safety and efficacy of Sangrow Decotion, diet and exercise for the treatment of type 2 diabetes. Previous study has shown that this therapeutic regimen is safe and effective.
Study Started
Mar 31
2016
Primary Completion
Mar 31
2017
Anticipated
Study Completion
Jul 31
2017
Anticipated
Last Update
Apr 27
2016
Estimate

Dietary Supplement SanGrow Decoction

SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.

SanGrow Experimental

Patients will be given SanGrow Decoction 150 ml per day for 3 months.

Criteria 

Inclusion Criteria:

Type II diabetes mellitus patients who have received medical treatment for more than 3 months
Patients willing to sign written informed consent form

Exclusion Criteria:

Patients unable or unwilling to comply with the requirements of the protocol
Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
Life expectancy < 6 months due to concomitant illnesses.
No Results Posted